RxDoctor Payments Data

Phillip Becker, OD

Optometrist · Mitchell, SDNPI 1407344559

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $2,325 of the $2,741 with a category attached, or 84.8%. Alcon accounts for 90.4% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2021 at $2,416 and has fallen 97.3% since, to $66 in 2025. Among optometrist clinicians in SD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,741in general payments, 2019–2025

Across 27 payments — averaging $101.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • Shire North American Group Inc$53
  • AbbVie$43
  • Coopervision Inc.$36
  • Oyster Point Pharma, Inc.$28
  • Rxsight Inc$23
  • plus $80 from 4 others
$109in research payments, 2019–2025

Across 1 payment — averaging $108.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$109

What the payments were for

  • Speaking & faculty fees$2,32585%
  • Food & beverage$39714%
  • Gifts$191%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,741 in reported general payments places this provider in the 90th percentile of 206 optometrist providers in South Dakota.

See all optometrist providers in South Dakota

Medicare billing

Part B allowed, 2024
$41,495
Medicare patients
242
Services billed
501

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine19$12,203
Restasis MultidoseCyclosporine11$7,266
Latanoprost95$498
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha15$141
Timolol Maleate14$62

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Restasis Multidose$43$19,46930 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 206 optometrist providers in South Dakota.

Other optometrist in Mitchell

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →